Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple MyelomaDavid H. Henry, Howard Yeh, Luís Costa et al.|Journal of Clinical Oncology|2011Cited by 1.3k
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trialsAllan Lipton, Susie Jun, Karim Fizazi et al.|European Journal of Cancer|2012Cited by 588
Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumorsDavid H. Henry, Howard Yeh, Saroj Vadhan‐Raj et al.|Supportive Care in Cancer|2013Cited by 182
Hypocalcaemia in patients with metastatic bone disease treated with denosumabJean-Jacques Body, Paul J. Kostenuik, Henry G. Bone et al.|European Journal of Cancer|2015Cited by 150
Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristicsAllan Lipton, Ada Braun, Karim Fizazi et al.|European Journal of Cancer|2015Cited by 114